Folic acid-based multivitamin therapy to prevent stroke: The jury is still out

Stroke

Volumn 35, Issue 8, 2004, Pages 1995-1998

  Hankey, Graeme J ^a,b   Eikelboom, John W ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Clinical trials; Folic acid; Homocysteine; Stroke prevention; Vitamin B complex

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTIOXIDANT; CYANOCOBALAMIN; CYTOSINE; FOLIC ACID; HOMOCYSTEINE; HORMONE; MULTIVITAMIN; PLACEBO; PYRIDOXINE; RIBOFLAVIN; THYMIDINE;

BLOOD LEVEL; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MEGADOSE; ENZYME SUBSTRATE; FOLLOW UP; GENE MUTATION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; LIFESTYLE; LOW DRUG DOSE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DIETARY SUPPLEMENTS; FOLIC ACID; HOMOCYSTEINE; HUMANS; RISK;

EID: 3242749158     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000135228.20619.ad     Document Type: Review

References (27)

1. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407-413.
2. Eikelboom JW, Lonn E, Genest J Jr, Hankey GJ, Yusuf S. Homocyst(e)ine and cardiovascular disease. A critical review of the epidemiological evidence. Ann Intern Med. 1999;131:363-375.
3. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischaemic stroke due to large- and small-artery disease but not other etiological subtypes of ischemic stroke. Stroke. 2000;31:1069-1075.
4. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22:6-13.
5. Ford ES, SJ Smith, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol. 2002;31:59-70.
6. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, Furie KL. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke. Results of a meta-analysis. Neurology. 2002;59: 529-536.
7. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
8. Kleik M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies Collaboration Group. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023-2031.
9. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202-1208.
10. Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF. Vitamin Intervention for Stroke Prevention (VISP) Trial: rationale and design. Neuroepidemiology. 2001;20:16-25.
11. Toole JF, Malinow R, Chambless L, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang C-H, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
13. Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2003;139:56-70.
14. 12 intakes in relation to risk of stroke among men. Stroke. 2004;35:169-174.
15. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
16. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998;338:1009-1015.
17. Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med. 2001;135: 133-137.
18. 12 in reduction of risk of vascular disease. Lancet. 2002;359:227-228.
19. The VITATOPS Trial Study Group. The VITATOPS (VITAmins To Prevent Stroke) Trial: rationale and design of an international, large, simple, randomized trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13:120-126.
20. Wilmink HW, Stroes ES, Erkelens WD, Gerritsen WB, Wever R, Banga JD, Rabelink TJ. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2000;20:185-188.
21. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol. 1999;34:2002-2006.
22. Verhaar MC, Wever RM, Kastelein JJ, van Loon D, Milstien S, Koomans HA, Rabelink TJ. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation. 1999;100:335-338.
23. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet. 1998;351:263.
24. 6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet. 2000;355:517-522.
25. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593-1600.
26. 3 on clinical outcome after percutaneous coronary intervention. JAMA. 2002;288:973-979.
27. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kalimayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673-2681.